Associate Professor of Medicine
Hematology
Harold A. Harvey, MB
|
|
Give Review
Harold A. Harvey, MB works in the field of Hematology. He received awards:"Regional Top Doctor". Harold Harvey is also a published MD. He has 100 publication published. The most recent publication is: Abnormal aminopyrine metabolism in patients with hepatic neoplasm. Detection by breath test. Harold A. Harvey, MB accepts Medicare payments and is registered with Medicare.gov.
Publications
- Molecular profiling of 6,892 colorectal Cancer samples suggests different possible treatment options specific to metastatic sites.
- Predicting therapy response in live tumor Cells isolated with the flexible micro spring array device.
- Update on clinical trials: genetic targets in breast Cancer.
- Integrated regulation of autophagy and apoptosis by EEF2K controls Cellular fate and modulates the efficacy of curcumin and velcade against tumor Cells.
- Identifying Circulating Tumor Stem Cells That Matter: The Key to Prognostication and Therapeutic Targeting.
- Biology of bone metastases: causes and consequences.
- Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast Carcinoma on hormone therapy.
- Optimizing bisphosphonate therapy in patients with breast Cancer on endocrine therapy.
- Hypercalcemia and gallium nitrate.
- Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast Cancer.
- Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast Cancer.
- Luteinizing hormone-releasing hormone agonists in the treatment of breast Cancer.
- Maintenance etidronate in the prevention of malignancy-associated hypercalcemia.
- Aminoglutethimide as treatment of postmenopausal women with advanced breast Carcinoma.
- Adjuvant antiplatelet therapy with aspirin in colo-rectal Cancer.
- Incidentally detected thrombosed vein during 67Ga citrate scanning.
- Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian Carcinoma.
- Radioimmunoassay of a Cancer-related glycoprotein. Circulating levels.
- Leuprolide: a review of its effects in animals and man.
- Androgen priming and response to chemotherapy in advanced prostatic Cancer.
- Gonadotropin releasing hormone (GnRH) Analogs for the treatment of breast and prostatic carcinoma.
- Advanced head and neck Cancer: low-dose, split-course radiation therapy and simultaneous infusion of 5-fluorouracil and cisplatin.
- Endocrine treatment of breast Cancer in women.
- Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic Carcinoma.
- Cis-platinum ototoxicity: clinical experience and temporal bone histopathology.
- Phase I study of a 5-day schedule of mitoxantrone (dihydroxyanthracenedione).
- Addition of etoposide to cyclophosphamide, doxorubicin, and vincristine for remission induction and survival in patients with small cell lung Cancer.
- A randomized trial of aminoglutethimide +/- estrogen before chemotherapy in advanced breast Cancer.
- A phase II study of Catrix-S in solid tumors.
- Aminoglutethimide-induced hematologic toxicity: worldwide experience.
- Phase II study of mitolactol in metastatic Malignant melanoma.
- A method for collecting detailed data on direct and indirect medical expenses of Cancer patients.
- Treatment of advanced epidermoid Carcinoma of the head and neck using methotrexate, bleomycin and cis-platinum.
- Symptomatic malignant melanoma of the gastrointestinal Tract. Operative treatment and survival.
- Raynaud's phenomenon with vinblastine and bleomycin.
- Pancytopenia induced by aminoglutethimide in the treatment of breast Cancer.
- Raynaud''s phenomenon as a side effect of chemotherapy with vinblastine and bleomycin for testicular Carcinoma.
- Abnormal aminopyrine metabolism in patients with hepatic neoplasm. Detection by breath test.
- A decision-theoretic evaluation of early stopping rules.
- Androgen depletion/repletion in combination with chemotherapy: strategy for secondary treatment of metastatic prostatic Cancer.
- Hormone stimulation and chemotherapy in advanced prostate Cancer: interim analysis of an ongoing randomized trial.
- Decreased prevalence of immediate hypersensitivity (atopy) in a Cancer population.
- Aromatase inhibitor development for treatment of breast Cancer.
- Use of aromatase inhibitors in breast Carcinoma.
- The in vitro interaction of RA-233 and several interferons on human Cell lines.
- The in vitro interaction of alpha-difluoromethyl ornithine (DFMO) and several interferons on human Cell lines.
- Airway obstruction due to Lymphoma of the larynx and trachea.
- Hormone stimulation and chemotherapy in advanced prostate Cancer: preliminary results of a prospective controlled clinical trial.
- Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast Cancer: correlation of hormonal data with clinical responses.
- Intravenous vinorelbine as first-line and second-line therapy in advanced breast Cancer.
- A randomized trial comparing surgical Adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer.
- Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver Disease or on anticonvulsant drug therapy: diazepam breath test and corr...
- Venous thrombosis as a side effect of tamoxifen treatment.
- Baseline serum NTx levels are prognostic in metastatic breast Cancer patients with bone-only metastasis.
- Mechanism of action of aminoglutethimide in breast Cancer.
- Unmet needs of persons with Cancer in Pennsylvania during the period of terminal care.
- Use of aminoglutethimide and hydrocortisone as a "medical Adrenalectomy" for treatment of breast carcinoma.
- Evaluation of CEA and GCDFP-15 plasma level during hormonally induced Cancer stimulation.
- Nonmedical costs to patients and their families associated with outpatient chemotherapy.
- Urinary polyamine levels in patients with gastrointestinal malignancy.
- Urinary polyamine levels in patients with localized malignancy.
- Decreased hepatic drug demethylation in patients receiving chemo-immunotherapy.
- Corynebacterium parvum versus BCG adjuvant immunotherapy in human Malignant melanoma.
- Clinical effect of aminoglutethimide, medical Adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma.
- Estrogen receptor status in inflammatory breast Carcinoma.
- Comparison of DES vs DES + chlorambucil in women with first recurrence of breast Cancer.
- Inhibition of aromatase as treatment of breast Carcinoma in postmenopausal women.
- Treatment of breast Cancer with gonadotropin-releasing hormone.
- Closing remarks to the conference, Aromatase: New Perspectives for Breast Cancer.
- Kinetic, hormonal and clinical studies with aminoglutethimide in breast Cancer.
- Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast Cancer.
- Clinical studies with aminoglutethimide in advanced breast Carcinoma.
- FAM chemotherapy +/- aminoglutethimide in the treatment of pancreatic Carcinoma.
- Correlation of aromatase activity with histological differentiation of breast Cancer--a morphometric analysis.
- Hormonal and immunological regulation of 2', 5'-oligoadenylate synthetase activity in human peripheral blood mononuclear Cells.
- Comparison of surgical Adrenalectomy to medical Adrenalectomy in patients with metastatic carcinoma of the breast.
- Growth inhibition of breast Cancer cell lines by combinations of anti-P185HER2 monoclonal antibody and cytokines.
- Plasma prostaGlandins across the tumor bed of patients with gynecologic malignancy.
- A study of prostaGlandin E2, parathormone, and response to indomethacin in patients with hypercalcemia of malignancy.
- The management of hypercalcemia of malignancy.
- Androgen depletion and repletion as a means of potentiating the effect of cytotoxic chemotherapy in advanced prostate Cancer.
- Interleukin-2 and interferon-alpha-2a outpatient therapy for metastatic renal Cell carcinoma.
- Emerging role of aromatase inhibitors in the treatment of breast Cancer.
- Chemotherapy plus RA233 in the treatment of oat cell lung Cancer.
- Immunologic monitoring studies in advanced Cancer patients treated with recombinant human gamma interferon (IFN-gamma 4A).
- Elevated plasma platelet-derived growth factor B-chain levels in Cancer patients.
- Medical Adrenalectomy with aminoglutethimide: clinical studies in postmenopausal patients with metastatic breast carcinoma.
- Glycoproteins and human Cancer: II. Correlation between circulating level and disease status.
- Glycoproteins and human Cancer. 1. Circulating levels in Cancer serum.
- Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast Cancer.
- Combined chemoradiotherapy for unresectable pancreatic Cancer.
- Prognostic value of breast Cancer aromatase.
- A phase I study of hepatic arterial infusion using difluoromethylornithine.
- A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.
- The impact of 2D versus 3D quantitation of tumor bulk determination on current methods of assessing response to treatment.
- Immunosuppression and human cancer: role of prostaGlandins.
- Plasma prostaGlandins in hypercalcemic patients with neoplastic disease.
- Phase I trial of recombinant platelet factor 4 (rPF4) in patients with advanced coloRectal carcinoma.
- Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast Cancer cells.
Schools
University of The West Indies Faculty of Medicine
Queen Elizabeth Hospital
Faulkner Hospital
Lemuel Shattuck Hospital
Lemuel Shattuck Pondville H
Tufts New Eng Med Center
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Amerihealth
- Assurant Health
- Blue Card PPO
- Capital Blue Cross
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Coventry Health America PPO
- Emblem Health
- First Health (Coventry Health Care) PPO
- Gateway Health Plan
- Community Blue PPO
- Humana
- MagnaCare
- Medicaid
- Medicare MCR
- Medico
- Meritain Health
- PHCS Network PPO
- National Elevator
- Tricare
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
- Universal American
- UPMC Health Plan
Awards
- Regional Top Doctor
Education
-
Tufts Medical Center -
University of the West Indies Faculty of Medical Sciences
Hospital
-
Penn State Milton S. Hershey Medical Center
Drug Facts
| NPI NUMBER | 1265480990 | |
| NPPES Provider LastName | HARVEY | |
| NPPES Provider FirstName | HAROLD | |
| NPPES Provider ZIPCode | 170332360 | |
| NPPES Provider State | PA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 727.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 83.0 | |
| Percent Opioid Claims | 11.42 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1265480990 |
| Last Name Of The Provider | HARVEY |
| First Name Of The Provider | HAROLD |
| View All |
Similar Doctors
|
|
Dr. Leah Cream, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ayodele G. Ayoola, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David F. Claxton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James O. Ballard, MD |
|
|
Dr. William A. Flood Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Witold B. Rybka, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mhd Y. Al-Marrawi, MD |
|
|
Dr. Julie A. Campbell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward J. Gunther, MD
This Doctor is OpenDoctor Recommended.
|